{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=104", "query": { "condition": "Cancer", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 50397, "total_pages": 5040, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T20:33:53.977Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07140679", "title": "Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Localized Colon Carcinoma", "Stage IIB Colon Cancer AJCC v8", "Stage IIC Colon Cancer AJCC v8", "Stage III Colon Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-09-19", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Johns Creek", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140679" }, { "nct_id": "NCT03845296", "title": "Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "Loss of Heterozygosity", "Lung Non-Small Cell Squamous Carcinoma", "Recurrent Large Cell Lung Carcinoma", "Recurrent Lung Adenocarcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Non-Squamous Non-Small Cell Lung Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 64, "start_date": "2019-04-16", "completion_date": "2024-09-21", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 950, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03845296" }, { "nct_id": "NCT00801346", "title": "Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fatigue", "Leukemia", "Long-term Effects Secondary to Cancer Therapy in Children" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "metabolic assessment", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Year to 20 Years" }, "enrollment_count": 224, "start_date": "2008-11", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 3, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801346" }, { "nct_id": "NCT04099888", "title": "PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma" ], "interventions": [ { "name": "Fimaporfin and Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PCI Biotech AS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-05-23", "completion_date": "2022-05-06", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 6, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099888" }, { "nct_id": "NCT00256308", "title": "Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-02", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2018-05-01", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256308" }, { "nct_id": "NCT04542135", "title": "Sulindac and Breast Density in Women at Risk of Developing Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sulindac Pill", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alison Stopeck", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "35 Years to 70 Years · Female only" }, "enrollment_count": 61, "start_date": "2020-11-20", "completion_date": "2025-05-19", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 2, "location_summary": "Los Angeles, California • Stony Brook, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542135" }, { "nct_id": "NCT01014208", "title": "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Large-Cell, Diffuse" ], "interventions": [ { "name": "OFATUMUMAB + DHAP", "type": "DRUG" }, { "name": "RITUXIMAB + DHAP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2010-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-08-07", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 16, "location_summary": "Sacramento, California • New Haven, Connecticut • Chicago, Illinois + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01014208" }, { "nct_id": "NCT00858117", "title": "A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-09-26", "completion_date": "2013-01-24", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858117" }, { "nct_id": "NCT03260491", "title": "U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "HER3-DXd (FL-DP)", "type": "DRUG" }, { "name": "HER3-DXd (CTM-1 Lyo-DP)", "type": "DRUG" }, { "name": "HER3-DXd (CTM-3 Lyo-DP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2017-10-30", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 16, "location_summary": "Duarte, California • La Jolla, California • Long Beach, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03260491" }, { "nct_id": "NCT01483274", "title": "Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2015-03", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-07T20:33:53.977Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483274" } ] }